These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16049884)

  • 21. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of HBV/HCV coinfection: releasing the enemy within.
    Gordon SC; Sherman KE
    Gastroenterology; 2009 Feb; 136(2):393-6. PubMed ID: 19105960
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of hepatitis C infection: towards eradication of chronic virus].
    Ahola T; Kaukinen P
    Duodecim; 2012; 128(18):1911-7. PubMed ID: 23088003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SASLT practice guidelines: management of hepatitis C virus infection.
    Alghamdi AS; Sanai FM; Ismail M; Alghamdi H; Alswat K; Alqutub A; Altraif I; Shah H; Alfaleh FZ;
    Saudi J Gastroenterol; 2012 Sep; 18 Suppl(Suppl 1):S1-32. PubMed ID: 23006491
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical decisions. Management of incidental hepatitis C virus infection.
    Afdhal NH; Lok AS; Di Bisceglie AM
    N Engl J Med; 2009 Apr; 360(18):1902-6. PubMed ID: 19403909
    [No Abstract]   [Full Text] [Related]  

  • 26. Future trends in managing hepatitis C.
    McHutchison JG; Dev AT
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S51-61. PubMed ID: 15081103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
    Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
    Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history and management of hepatitis C infection after liver transplantation.
    Charlton M; Wiesner R
    Semin Liver Dis; 2004; 24 Suppl 2():79-88. PubMed ID: 15346250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.
    McGovern BH; Abu Dayyeh BK; Chung RT
    Hepatology; 2008 Nov; 48(5):1700-12. PubMed ID: 18972443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The scientific challenge of hepatitis C.
    Cohen J
    Science; 1999 Jul; 285(5424):26-30. PubMed ID: 10428695
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha.
    Wiegand J; Deterding K; Cornberg M; Wedemeyer H
    J Antimicrob Chemother; 2008 Nov; 62(5):860-5. PubMed ID: 18776191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent viral liver disease (hepatitis B and C) after liver transplantation.
    Olivera-Martínez MA; Gallegos-Orozco JF
    Arch Med Res; 2007 Aug; 38(6):691-701. PubMed ID: 17613360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute hepatitis C in 2005].
    Nguyen-Khac E
    Gastroenterol Clin Biol; 2005 Nov; 29(11):1149-56. PubMed ID: 16505761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic hepatitis C virus infection.
    Malnick SD; Beergabel M; Lurie Y
    Ann Pharmacother; 2000 Oct; 34(10):1156-64. PubMed ID: 11054985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist.
    Fabrizi F; Locatelli F
    Nephrol Dial Transplant; 1999 Sep; 14(9):2079-81. PubMed ID: 10489210
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acute hepatitis. Biological hepatic anomalies in asymptomatic persons].
    Buffet C
    Rev Prat; 2006 Sep; 56(13):1473-9; quiz 1479. PubMed ID: 17002075
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical guidelines on the management of hepatitis C.
    Booth JC; O'Grady J; Neuberger J;
    Gut; 2001 Jul; 49 Suppl 1(Suppl 1):I1-21. PubMed ID: 11413125
    [No Abstract]   [Full Text] [Related]  

  • 38. Diagnosis, management, and treatment of hepatitis C: an update.
    Ghany MG; Strader DB; Thomas DL; Seeff LB;
    Hepatology; 2009 Apr; 49(4):1335-74. PubMed ID: 19330875
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C comorbidities affecting the course and response to therapy.
    El-Zayadi AR
    World J Gastroenterol; 2009 Oct; 15(40):4993-9. PubMed ID: 19859990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver.
    Can J Gastroenterol; 2000; 14 Suppl B():5B-20B. PubMed ID: 10938500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.